A $100 Billion Psychedelics Opportunity
Undervalued Better Plant Sciences Inc. (STOCK:BOSQF) Aggressively Pushing into Psilocybin Market
Psychedelic drugs aren’t just some “here today, gone tomorrow” phenomenon.
Not by a long shot.
Instead, such treatments – like psilocybin mushrooms — are only just beginning to boom.
It’s part of the reason that Eight Capital estimates the total market for mental health treatment could be valued at up to $100 billion(1)
Just days ago, the Canadian government allowed four terminally ill patients with cancer to receive psilocybin therapy to help ease end-of-life distress. This is the first time in 46 years that an exemption has been given in Canada for patients to access such treatment.(2)
There’s plenty of support for it in the U.S., too.
For example Denver, Oakland, and Santa Cruz have recently legalized its use. Washington, D.C. and Oregon residents will vote on its legalization in the upcoming November 2020 elections.(3)
The best part — such drugs are already proving to be a major game changer for millions of people all over the world. Countless studies are already proving such treatments can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders.
Plus, with plenty of clinical trials supporting psychedelic treatments, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.
Psilocybin may also help treat eating disorders and obesity, creating sizable opportunity for Better Plant Sciences Inc. (STOCK:BOSQF).
Just Who is Better Plant Sciences Inc. (STOCK:BOSQF)?
Plant Sciences Inc. (STOCK: BOSQF) is a vertically integrated company that develops, licenses and sells plant-based products, formulas and conducts research into plant-based medicine in the $4.2 trillion global wellness market.(4)
After years of research and development, the company now has over 200 formulations, 12+ pending patents, and their hard work appears to be paying off as they look to aggressively expand into the multi-billion dollar plant-based market.
It’s also deeply involved with the psychedelics boom – with psilocybin as a potential treatment for weight issues.
That’s because psilocybin activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today.
“This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.”
Better Plant Sciences Just Filed Several Patent Applications Relating to Psilocybin
Better Plant Sciences Inc.’s majority owned subsidiary NeonMind has now filed six U.S. provisional patent application in the U.S. for the invention relating to therapeutic administration of psilocybin or psilocin, combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.
One of the provisional patents is for a guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the Psilocybin are felt by the patient.
The psychedelic assisted psychotherapy is designed to assist in gathering insights from positive psychedelic experiences, to be integrated into everyday life and to help plan, prepare and make sense of psychedelic experiences for a therapeutic result.
In addition, NeonMind has retained contract research organization Translational Life Sciences Inc. to design and plan an initial preclinical study using psilocybin which is anticipated to begin in the fall of 2020. The preclinical study is anticipated to provide data to design phase 2 human clinical trials to test Psilocybin as a weight loss treatment. The phase 2 clinical trials are anticipated to begin in 2021, subject to receiving all required regulatory approvals.
NeonMind also just announced its submission of an application to Health Canada for an exemption to use a controlled substance for scientific purposes, pursuant to Section 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (a “Section 56 Exemption”) for NeonMind’s planned preclinical trial using psilocybin.
In May 2020, NeonMind completed the design of its preclinical study focused on using psilocybin as a treatment for weight loss and food cravings.
NeonMind has identified a laboratory at a Canadian university in which to conduct the Study and the Section 56 Exemption application was submitted on July 27, 2020 by the person at the Lab who is expected to be the lead investigator in the Study.
However, it’s not just psychedelics driving growth.
Demand for Plant-Based Products is Just Beginning to Sprout
Demand for plant-based products has created a multi-billion-dollar revolution, creating a lucrative opportunity for Better Plant Sciences Inc. (STOCK:BOSQF).
U.S. retail sales of plant-based foods grew approximately 11.4% in 2019 to about $5 billion, according to a SPINS sales data report shared by The Good Food Institute and the Plant Based Foods Association, as noted by Forbes.
Or, look at the health and beauty market.
The global vegan cosmetics market could be worth up to $20.8 billion over the next five years, according to Grand View Research. All on the belief that plant-based products are far better for their health, consumers are pushing for natural alternatives.(6)
At the moment nearly a third of Millennials are already purchasing skin care products with organic, sustainable, or plant-based attributes, says Linkage Research.
What we’re witnessing is a massive trend that isn’t likely to die off any time soon.
Better Plant Sciences (STOCK:BOSQF) Acquired JUSU Plant-Based Assets for $2.25 Million
Better Plant Sciences entered into an agreement to acquire JUSU branded plant-based assets from JUSU Bar Inc., JUSU Life Inc. and JUSU Cbd Inc. The assets include all inventory, packaging, raw ingredients, and intellectual property related to 300 plant-based products for the home, body and baby, as well as the e-commerce sites where the products are sold, the customer lists and all intangible assets relating to the chain of juice bars operated in British Columbia and Alberta under the name JUSU.
JUSU is a western Canadian health, wellness and lifestyle brand. It is positioned as a full spectrum wellness brand for premium plant-based products.
The asset purchase includes 300 JUSU products including:
- JUSU Life: (156 products) cleaning and germ-fighting products, essential oils and aromatherapy
- JUSU Body: (80 products) baby products, body lotions and washes, bug and tick spray, hair and face products, soaps, deodorants, shaving creams and sun care
- JUSU Bar: (35 products) cold-pressed juices, nut milks, health shots, smoothies and smoothie bowls, cold-brew, plant-based coffees, wraps and chia cups
- JUSU Cbd: (30 formulas) cold-pressed juices, elixirs, health shots, skin care, cosmetics, aromatherapy, supplements and pet care
Better Plant Sciences (STOCK:BOSQF) is Also Led by a Powerhouse Team
With significant potential industry growth, a “Hall of Fame” level management team of experienced executives and a significant first-to-market advantage, Better Plant Sciences Inc. appears well positioned for the months and years ahead.
Better Plant Sciences Inc.’s highly experienced leadership team is made up of proven leaders with extensive backgrounds and success stories from a variety of relevant industries, including…
Co-Founder, President & CEO, Director
Penny is a serial entrepreneur and securities lawyer with over two decades of experience in online music, international film distribution, mobile payments, blockchain technology, crowdsourcing, renewable energy, pharmaceuticals, e-commerce and c*nnabis. She is also co-founder of Merus Labs Inc. (TSX:MSL, NASDAQ:MSLI-Q), which was acquired by Norgine B.V. in 2017 for $342 million. Penny was recognized in PROFIT Magazine’s W100 most successful entrepreneurs and included in PROFIT 500 Fastest Growing companies in 2015 and 2016.
Chief Operating Officer, Plant Sciences Inc.
Among her career achievements, Tamara was instrumental in the growth of Canadian fashion retailer Aritzia (TSX:ATZ) as its Vice President, Corporate Operations and Executive Vice President, People & Culture. When she joined in 2001, Aritzia had 10 stores and 30 head office employees, and Melck built several of the corporate backend functions from scratch, helping Aritzia to scale its operations and achieve $743M in annual revenue and to reach a market capitalization of over $1 billion when she left in 2017.
Melck was a member and former chair of the Executive Committee of Aritzia, and she directly led and oversaw numerous departmental and cross-functional projects of all sizes to build the necessary infrastructure to enable growth. Aritzia is a vertically integrated, innovative design house of exclusive fashion brands. It reported net revenue of $743.3 million in Fiscal 2018.
Jeff B. Smith
Chairman of the Advisory Board, Plant Sciences Inc.
Jeff Smith was the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies, the world’s largest and most diversified healthcare company with worldwide sales of US$76 billion in 2017.
In his most recent role as Johnson & Johnson Company Group Chairman for Consumer North America, Jeff delivered strong organic growth, new growth levers such as Beauty Special Ops and the OceanX partnership, and oversaw several important strategic acquisitions including Vogue International LLC, La Lumière, and Neostrata. His division represented more than 42% of global revenue, delivering over US$6.5 billion in annual revenue with mid-single digit growth rates; spent over US$1 billion in marketing investment; delivered consistent market share gains and doubled the regional profitability. Jeff was on the Johnson & Johnson’s Group Operating Committee Executive.
Prior to acting as Chairman of Johnson & Johnson, in 2011 Jeff was appointed President, U.S. Skincare in the newly formed North American region. Jeff had full P&L responsibility for the Baby (JOHNSON’S®, AVEENO®) and Beauty Care divisions (NEUTROGENA®, AVEENO®, CLEAN & CLEAR®, LUBRIDERM® and KORRES® Natural products) within the United States. As President of Johnson & Johnson’s largest business unit, Jeff grew it from the third-largest skincare company to #1 in the U.S. over 3.5 years.
Corporate Secretary, General Counsel and Vice President, People, Plant Sciences Inc.
Amy Frankel has over 15 years of experience working with consumer product companies. In her various roles as in-house counsel, Amy has gained vast experience building, protecting and expanding international brands. Previously, Amy was Co-General Counsel of Aritzia LP (TSX: ATZ) and Associate General Counsel of Skechers USA Inc. (NYSE:SKX). Her expertise includes negotiating inbound and outbound licensing deals, developing intellectual property strategies, and managing international intellectual property portfolios. Amy’s experience also includes corporate governance for private and public US and Canadian companies, as well as a wide breadth of commercial matters, including distribution agreements and technology contracts.
Amy began her career as a business litigator in Los Angeles, appearing before numerous state and federal courts before moving in-house with Skechers. Amy practiced law in California for 10years prior to moving to Vancouver, BC. In 2008, she was admitted to the Law Society of British Columbia. Amy obtained her Bachelor’s degree from the University of California, Santa Barbara and her Juris Doctorate from the University of California, Hastings. She is licensed in California and British Columbia.
CFO, Plant Sciences Inc.
Rick Huang served as CFO of Hanwei Energy Services corporation (TSX: HE).
Rick has also served as CFO of several other publicly traded companies, where he has managed all aspects of finance, banking, compliance, accounting, reporting, internal control, admin, and supporting the board of directors in financial oversight. He also has supervised all aspects of accounting for various subsidiary companies in Canada, China, Russia and Kazakhstan and consolidations under IFRS.
He has worked on investor relations activities, roadshow AGM preparations, and licensing agreements and has led various public equity financing projects raising funds of up to $90 million and leading acquisitions of up to $80 million. Rick has negotiated for international joint ventures, including drafting shareholders’ agreements, establishing international legal entities, and assets transfers. Rick also serves as Chair of the Audit Committee for Datable Technology Corp. (TSXV: TTM) and previously Chair of the Governance Committee and member of the Audit Committee of Poydras Gaming Finance Corp. (TSXV: PYD).
There are many compelling reasons to consider Better Plant Sciences Inc. (STOCK:BOSQF).
Three, Better Plant Sciences Inc. is exposed to a potential $100 billion p*sychedelics market, as the company delves into psilocybin treatment studies for health issues, such as obesity. The company currently has 6 unique patent applications submitted, opening up a large pipeline for potential drug development.
Two, it’s exposed to a global vegan cosmetics market that could be worth up to $20.8 billion over the next five years. Better, it has more than 200 plant-based formulations.
Three, Better Plant Sciences Inc. is aggressively building strong direct to consumer strategies, and just recently announced its natural, plant-based Urban Juve products are now available in select Canadian retail chain Pharmasave stores in multiple provinces across Canada. Pharmasave stores in British Columbia, Ontario, Manitoba, and Saskatchewan are already carrying the Urban Juve Hand Sanitizer Liquid Spray.